$160 Million is the total value of Tamarack Advisers, LP's 31 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 47.1% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PCRX | Sell | PACIRA PHARMACEUTICALS INC | $12,084,000 | +37.0% | 265,000 | -2.9% | 7.55% | +21.1% |
SPNC | Sell | SPECTRANETICS CORP | $8,738,000 | +8.2% | 300,000 | -9.0% | 5.46% | -4.4% |
JAZZ | Sell | JAZZ PHARMACEUTICALS PLC | $8,272,000 | -1.5% | 57,000 | -26.0% | 5.17% | -13.0% |
TDOC | Sell | TELADOC INC | $7,625,000 | +11.2% | 305,000 | -26.6% | 4.76% | -1.8% |
LH | Sell | LABORATORY CRP OF AMER HLDGS | $6,887,000 | +5.2% | 48,000 | -5.9% | 4.30% | -7.1% |
ATHN | Sell | ATHENAHEALTH INC | $3,381,000 | -21.6% | 30,000 | -26.8% | 2.11% | -30.8% |
NXTM | Sell | NXSTAGE MEDICAL INC | $2,951,000 | -69.4% | 110,000 | -70.1% | 1.84% | -72.9% |
QTNT | Sell | QUOTIENT LTD | $350,000 | -27.7% | 50,000 | -50.0% | 0.22% | -36.0% |
AMGN | Sell | AMGN US 04/21/17 C175listed option | $2,000 | -100.0% | 130 | -99.6% | 0.00% | -100.0% |
SYK | Exit | SYK US 01/20/17 P115listed option | $0 | – | -250 | -100.0% | -0.02% | – |
HSIC | Exit | HSIC US 01/20/17 P155listed option | $0 | – | -360 | -100.0% | -0.12% | – |
LMNX | Exit | LUMINEX CORPequity | $0 | – | -135,000 | -100.0% | -1.93% | – |
IPXL | Exit | IMPAX LABORATORIES INCequity | $0 | – | -257,500 | -100.0% | -2.41% | – |
SCI | Exit | SERVICE CORP INTERNATIONALequity | $0 | – | -125,000 | -100.0% | -2.51% | – |
BIO | Exit | BIO-RAD LABORATORIES-Aequity | $0 | – | -49,000 | -100.0% | -6.32% | – |
HOLX | Exit | HOLOGIC INCequity | $0 | – | -230,000 | -100.0% | -6.53% | – |
ARIA | Exit | ARIAD PHARMACEUTICALS INCequity | $0 | – | -850,000 | -100.0% | -7.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VERADIGM ORD | 32 | Q3 2023 | 13.9% |
STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
ATRICURE ORD | 29 | Q3 2023 | 7.6% |
PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
HOLOGIC INC | 17 | Q1 2022 | 6.5% |
SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
Correvio Pharma Corp. | February 15, 2019 | ? | ? |
Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-09 |
13F-HR | 2023-11-16 |
13F-HR | 2023-08-10 |
SC 13D/A | 2023-06-22 |
13F-HR | 2023-05-11 |
13F-HR | 2023-02-13 |
SC 13D/A | 2022-12-01 |
13F-HR | 2022-11-15 |
13F-HR | 2022-08-16 |
13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.